P2Y12 inhibitors in acute coronary syndromes: How do we choose the best drug for our patients?

Steen D. Kristensen; Erik L. Grove; Anne-Mette Hvas

doi:10.1160/TH12-06-0430

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2012; 108(02): 203-205
DOI: 10.1160/TH12-06-0430

Invited Editorial Focus

Schattauer GmbH

P2Y12 inhibitors in acute coronary syndromes: How do we choose the best drug for our patients?

Steen D. Kristensen

¹Department of Cardiology, Aarhus University Hospital, Denmark

,

Erik L. Grove

¹Department of Cardiology, Aarhus University Hospital, Denmark

,

Anne-Mette Hvas

²Department of Clinical Biochemistry, Aarhus University Hospital, Denmark

References
1 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
2 Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011; 105 (Suppl. 01) S75-S81.
3 Steiner S, Moertl D, Chen L. et al. Network metaanalysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost 2012; 108: 318-327.
4 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
5 Sibbing D, Byrne RA, Bernlochner I. et al. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106: 191-202.
6 Montalescot G, Sideris G, Cohen R. et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-223.
7 Capranzano P, Tamburino C, Capodanno D. et al. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost 2011; 106: 1149-1157.
8 Jakubowski JA, Li YG, Payne CD. et al. Absence of „rebound” platelet hyperreactivity following cessation of prasugrel. Thromb Haemost 2011; 106: 174-176.
9 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
10 Tantry US, Bliden K P, Wei C. et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010; 03: 556-566.
11 Mehta SR, Bassand JP, Chrolavicius S. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942.
12 Mehta SR, Tanguay JF, Eikelboom JW. et al. Doubledose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
13 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
14 Wiviott SD, Braunwald E, Angiolillo DJ. et al. Greater clinical benefit of more intensive oral anti-platelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
15 Grove EL, Gregersen S. Antiplatelet Therapy in Patients with Diabetes Mellitus. Curr Vasc Pharmacol 2012; 10: 494-505.
16 Montalescot G, Wiviott SD, Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731.
17 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
18 Steg PG, James S, Harrington RA. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-2141.
19 James SK, Roe MT, Cannon CP. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. Br Med J 2011; 342: d3527.
20 James S, Budaj A, Aylward P. et al. Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation Circulation 2010; 122: 1056-1067.
21 James SK, Storey RF, Khurmi N. et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012; 125: 2914-2921.
22 Hamm CW, Bassand JP, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
23 Li T, Puhan MA, Vedula SS. et al. Network metaanalysis-highly attractive but more methodological research is needed. BMC Med 2011; 09: 79.